ArticleBMC pediatrics2026
Trajectories of serum HIF-1α and BNIP3 are associated with injury severity and outcomes in pediatric traumatic brain injury: a prospective cohort study.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTraumatic brain injury (TBI) is a leading cause of pediatric mortality and long-term morbidity. Hypoxia-inducible factor-1α (HIF-1α) and its downstream target, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3), are key mediators of the hypoxia response and secondary brain injury. However, their temporal serum dynamics and clinical utility in pediatric TBI remain undefined. This study aimed to measure serum HIF-1α and BNIP3 levels at admission and day 7 post-TBI to evaluate their dynamic changes and relationship with injury severity and neurological outcome.
methodsIn this prospective single-center study, 169 pediatric TBI patients were enrolled. Serum HIF-1α and BNIP3 levels were quantified by ELISA at admission and day 7 post-injury. The relationship between biomarker dynamics (Δ, admission minus day 7), initial injury severity, and 6-month neurological outcome was analyzed.
resultsAdmission levels of both HIF-1α and BNIP3 were associated with TBI severity. At day 7 post-TBI, serum HIF-1α decreased significantly in mild TBI, while BNIP3 showed a non-significant trend. In contrast, both biomarkers decreased significantly in the moderate-to-severe TBI group. Among children with moderate-to-severe TBI, a smaller reduction (Δ) in HIF-1α and BNIP3 levels over the first week was independently associated with unfavorable outcome after adjusting for the motor Glasgow Coma Scale score (ΔHIF-1α: aOR = 0.149, P = 0.029; ΔBNIP3: aOR = 0.297, P = 0.046). This association remained robust in a sensitivity analysis of survivors.
conclusionThe early trajectories of serum HIF-1α and BNIP3 are independently associated with neurological outcomes in pediatric moderate-to-severe TBI. Serial measurement of these biomarkers may enhance risk stratification.
trial registrationChiCTR2100048753 (16/07/2021).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.